| scholarly article | Q13442814 |
| P356 | DOI | 10.1345/APH.1C292 |
| P698 | PubMed publication ID | 12503932 |
| P50 | author | Ronald N Jones | Q120908182 |
| P2093 | author name string | Alan H Mutnick | |
| Jeffrey T Kirby | |||
| CANCER Study Group | |||
| P2860 | cites work | Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations | Q31876731 |
| Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria | Q33756519 | ||
| Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia | Q33756523 | ||
| Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines | Q33970910 | ||
| Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. | Q33972587 | ||
| Surveillance of antimicrobial resistance--what, how and whither? | Q34083268 | ||
| 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer | Q34114674 | ||
| Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections | Q34198417 | ||
| Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy | Q34425743 | ||
| The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting | Q34509624 | ||
| Hospital-acquired infections: diseases with increasingly limited therapies | Q35113057 | ||
| Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital | Q39474457 | ||
| Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis | Q40582076 | ||
| Persistent fever in patients with neutropenia | Q40589566 | ||
| A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer | Q40614209 | ||
| Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region | Q43587147 | ||
| Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. | Q43587155 | ||
| Infections caused by viridans streptococci in patients with neutropenia | Q43996926 | ||
| MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. | Q54038516 | ||
| Extended-spectrum beta-lactamase in Proteus mirabilis. | Q54206520 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 47-56 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance | |
| P478 | volume | 37 |
| Q36746526 | Catheter-related bloodstream infections in hematology: time for standardized surveillance? |
| Q40496949 | Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens |
| Q43235040 | Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. |
| Q33588190 | Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients |
| Q57073881 | Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia |
| Q48192175 | Molecular confirmation of Enterococcus faecalis and E. faecium from clinical, faecal and environmental sources |
| Q37814101 | Mortality in a heterogeneous population of low-risk febrile neutropenic patients treated initially with cefazolin and tobramycin. |
| Q37215935 | Polymyxins revisited |
| Q43251098 | Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer. |
| Q33892651 | Rare bacterial isolates causing bloodstream infections in Ethiopian patients with cancer |
| Q37126210 | Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. |
Search more.